Cellumen Expands Discovery Toxicology Services with Cardiac Hypertrophy Panel
News Dec 26, 2008
Cellumen has announced a new Cellular Systems Biology (CSB) panel to predict cardiac hypertrophy earlier in the drug discovery and development process. By integrating this new panel into Cellumen’s CellCiphr Discovery Toxicology profiling services, drug companies can now save millions of dollars in development costs that are typically wasted by not identifying toxic compounds earlier, the company says.
“In the past 10 years, nearly 30 percent of all drugs in the United States have been withdrawn due to cardiotoxicity,” says Dr. Kate Johnston, Chief Scientific Officer and Vice President of Discovery Programs at Cellumen. “There are many tests available to detect electrophysiological abnormalities of the heart, but Cellumen’s Cardiac Hypertrophy Panel is the first systems-based panel to detect other development-limiting toxicities in cardiac cells.”
Cellumen’s Cardiac Hypertrophy Panel is designed to simultaneously measure eight distinct toxicity indicators in drug compounds including mitochondrial function, oxidative stress, apoptosis, and cellular hypertrophy. By leveraging Cellumen’s unique discovery toxicology approach, the panel quantifies both the mechanism and time course of toxicity.
In addition, the proprietary CellCiphr Classifier, an integral component of the panel, provides a quick, objective means to identify compounds that may cause cardiac-specific toxicity.
“The CellCiphr Cardiac Hypertrophy panel is the next step in helping the FDA realize their goal to first minimize and then to replace animal testing within the next 10 years,” says D. Lansing Taylor, PhD, CEO of Cellumen.
“By continuing to broaden its predictive panels across target organs, Cellumen is bringing its unique Cellular Systems Biology approach to more therapeutic programs and enabling more pharmaceutical companies to determine toxicity while reducing the reliance on animal tests. In turn, we are helping these companies not only reduce the percentage of available therapies that get withdrawn from the market for safety issues, but also significantly cut costs associated with drug discovery and development.”